Indolent B-Cell Lymphomas: Clinical Application of New Advances in Community Practice (NASP)

Learn current and novel best-practice strategies for the treatment of patients with follicular lymphoma and marginal zone lymphoma based on molecular profiling and clinical data with application to specialty pharmacy in this interactive, expert led 1-hour workshop.

To Register: On the Event Dates page click a date/time, click the blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Program Overview
  • Follicular Lymphoma
    • Prognostic and Predictive Biomarkers
    • Selecting Treatments
    • Key Safety Considerations
    • Considerations for Specialty Pharmacy
  • Marginal Zone Lymphoma
    • Prognostic and Predictive Biomarkers
    • Selecting Treatments
    • Key Safety Considerations
    • Considerations for Specialty Pharmacy
  • Closing Remarks and Question and Answer Session


Date / Time
Event Details


Elizabeth Brém, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
School of Medicine
University of California Irvine Medical Center
Orange, California

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jordan A. Miller, PharmD, BCPS, BCOP, CPP

Lead Pharmacist – Clinical Oncology Group
Clinical Pharmacist Practitioner, Myeloma & Lymphoma
University of North Carolina Medical Center
Hill, NC 

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with indolent B-cell lymphomas.

Target Audience
This program is intended for hematologists, medical oncologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with indolent B-cell lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order and interpret molecular profiling for appropriate patients with indolent B-cell lymphoma to guide therapy selection
  • Select treatment regimens for patients with MZL and FL based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes
  • Identify patients with indolent B-cell lymphoma who would likely benefit from enrollment on a clinical trial
  • Mitigate, monitor, and manage adverse events associated with newer therapeutic regimens used in the treatment of indolent B-cell lymphomas


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and ProCE, LLC. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-22-202-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) and ProCE, LLC require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO and ProCE policy. CCO and ProCE are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.